High-Fat Diet Intensifies MLL-AF9-Induced Acute Myeloid Leukemia through Activation of the FLT3 Signaling in Mouse Primitive Hematopoietic Cells

Using a MLL-AF9 knock-in mouse model, researchers discovered that consumption of a high-fat diet accelerates the risk of developing acute myeloid leukemia.
[Scientific Reports]
Hermetet, F., Mshaik, R., Simonet, J., Callier, P., Delva, L., & Quéré, R. (2020). High-fat diet intensifies MLL-AF9 -induced acute myeloid leukemia through activation of the FLT3 signaling in mouse primitive hematopoietic cells. Scientific Reports, 10(1), 16187. https://doi.org/10.1038/s41598-020-73020-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Increased Baseline RASGRP1 Signals Enhance Stem Cell Fitness during Native Hematopoiesis

The authors expanded RASGRP1 expression surveys in pediatric T-ALL and generated a RoLoRiG mouse model crossed to Mx1CRE to determine the consequences of induced RASGRP1 overexpression in primary hematopoietic cells.
[Oncogene]
Karra, L., Romero-Moya, D., Ksionda, O., Krush, M., Gu, Z., Mues, M., Depeille, P., Mullighan, C., & Roose, J. P. (2020). Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis. Oncogene, 1–15. https://doi.org/10.1038/s41388-020-01469-8 Cite
Abstract
Bookmark

No account yet? Register

0
Share

tagHi-C Reveals 3D Chromatin Architecture Dynamics during Mouse Hematopoiesis

Investigators introduced a low-input tagmentation-based Hi-C (tagHi-C) method to capture the chromatin structures of hundreds of cells. Using tagHi-C, they were able to map the spatiotemporal dynamics of chromatin structure in ten primary hematopoietic stem, progenitor, and differentiated cell populations from mouse bone marrow.
[Cell Reports]
Zhang, C., Xu, Z., Yang, S., Sun, G., Jia, L., Zheng, Z., Gu, Q., Tao, W., Cheng, T., Li, C., & Cheng, H. (2020). tagHi-C Reveals 3D Chromatin Architecture Dynamics during Mouse Hematopoiesis. Cell Reports, 32(13). https://doi.org/10.1016/j.celrep.2020.108206 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia

The authors describe the circuitry of a transactivation system responsible for oncogenic self-renewal. MLL recruited RNA polymerase II to unmethylated CpG-rich promoters by its CXXC domain and activated transcription by transcriptional regulators, including the AF4 family/ENL family/P-TEFb complex, DOT1L, and p300/CBP histone acetyl transferases.
[Cell Reports]
Miyamoto, R., Okuda, H., Kanai, A., Takahashi, S., Kawamura, T., Matsui, H., Kitamura, T., Kitabayashi, I., Inaba, T., & Yokoyama, A. (2020). Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia. Cell Reports, 32(13). https://doi.org/10.1016/j.celrep.2020.108200 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia

To identify determinants of bone marrow failure, researchers performed single-cell transcriptome profiling of primary hematopoietic stem and progenitor cells from Fanconi anemia patients.
[Cell Stem Cell]
Rodríguez, A., Zhang, K., Färkkilä, A., Filiatrault, J., Yang, C., Velázquez, M., Furutani, E., Goldman, D. C., Teresa, B. G. de, Garza-Mayén, G., McQueen, K., Sambel, L. A., Molina, B., Torres, L., González, M., Vadillo, E., Pelayo, R., Fleming, W. H., Grompe, M., … D’Andrea, A. D. (2020). MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. Cell Stem Cell, 0(0). https://doi.org/10.1016/j.stem.2020.09.004 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase III Bridging Study in Acute Myeloid Leukemia

Apollomics, Inc., announced APL-106 has received Investigational New Drug approval from the China National Medical Products Administration Center for Drug Evaluation. This approval enables the initiation of a Phase I pharmacokinetic and tolerability study and includes acceptance of a Phase III bridging study of APL-106 in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.
[Apollomics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Prelude Therapeutics Announces Dosing of First Patient in Phase I Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies

Prelude Therapeutics Incorporated announced that the first patient has been dosed in its first-in-human Phase I open-label, multicenter, dose-escalation study of PRT1419 in patients with relapsed/refractory hematologic malignancies. PRT1419, the company’s third clinical candidate, is designed to be an orally available, potent and selective MCL1 inhibitor.
[ Prelude Therapeutics Incorporated ]
Press Release
Bookmark

No account yet? Register

0
Share

Outcomes of Second Hematopoietic Stem Cell Transplantation Using Reduced‐Intensity Conditioning in an Outpatient Setting

Outpatient second hematoprogenitors transplant after reduced‐intensity conditioning at a single academic center was analyzed. Twenty‐seven consecutive adults who received an allogeneic hematopoietic stem cell transplantation (allo‐HSCT) after an initial auto‐ or allo‐HSCT from 2006 to 2019 were included.
[Hematological Oncology]
Jaime‐Pérez, J. C., Picón‐Galindo, E., Herrera‐Garza, J. L., & Gómez‐Almaguer, D. (n.d.). Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting. Hematological Oncology, n/a(n/a). https://doi.org/10.1002/hon.2812 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I

Orchard Therapeutics announced that the European Medicines Agency has granted Priority Medicines designation to OTL-203, an investigational ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy.
[Orchard Therapeutics plc.]
Press Release
Bookmark

No account yet? Register

0
Share

Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies

Vor Biopharma and Arbor Biotechnologies announced an agreement to use Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia.
[Vor Biopharma]
Press Release
Bookmark

No account yet? Register

0
Share

Ambrisentan, an Endothelin Receptor Type A-Selective Antagonist, Inhibits Cancer Cell Migration, Invasion, and Metastasis

In vitro, Ambrisentan inhibited both spontaneous and induced migration/invasion capacity of different tumor cells. Whole transcriptome analysis using RNAseq indicated Ambrisentan’s inhibitory effects on the whole transcriptome of resting and PAR2-activated COLO-357 cells, which tended to normalize to an unstimulated profile.
[Scientific Reports]
Kappes, L., Amer, R. L., Sommerlatte, S., Bashir, G., Plattfaut, C., Gieseler, F., Gemoll, T., Busch, H., Altahrawi, A., Al-Sbiei, A., Haneefa, S. M., Arafat, K., Schimke, L. F., Khawanky, N. E., Schulze-Forster, K., Heidecke, H., Kerstein-Staehle, A., Marschner, G., Pitann, S., … Cabral-Marques, O. (2020). Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Scientific Reports, 10(1), 15931. https://doi.org/10.1038/s41598-020-72960-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share